These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 27191002)

  • 1. Posttranslational Modifications and the Immunogenicity of Biotherapeutics.
    Jefferis R
    J Immunol Res; 2016; 2016():5358272. PubMed ID: 27191002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein aggregation and immunogenicity of biotherapeutics.
    Pham NB; Meng WS
    Int J Pharm; 2020 Jul; 585():119523. PubMed ID: 32531452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics.
    Wullner D; Zhou L; Bramhall E; Kuck A; Goletz TJ; Swanson S; Chirmule N; Jawa V
    Clin Immunol; 2010 Oct; 137(1):5-14. PubMed ID: 20708973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micro-Heterogeneity of Antibody Molecules.
    Mimura Y; Saldova R; Mimura-Kimura Y; Rudd PM; Jefferis R
    Exp Suppl; 2021; 112():1-26. PubMed ID: 34687006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo modifications of recombinant and human IgG antibodies.
    Liu H; Ponniah G; Zhang HM; Nowak C; Neill A; Gonzalez-Lopez N; Patel R; Cheng G; Kita AZ; Andrien B
    MAbs; 2014; 6(5):1145-54. PubMed ID: 25517300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications.
    Kuriakose A; Chirmule N; Nair P
    J Immunol Res; 2016; 2016():1298473. PubMed ID: 27437405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of therapeutic proteins: influence of aggregation.
    Ratanji KD; Derrick JP; Dearman RJ; Kimber I
    J Immunotoxicol; 2014; 11(2):99-109. PubMed ID: 23919460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance.
    Opolka-Hoffmann E; Jordan G; Otteneder M; Kieferle R; Lechmann M; Winter G; Staack RF
    MAbs; 2021; 13(1):1995929. PubMed ID: 34763611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunogenicity of antibody aggregates in a novel transgenic mouse model.
    Bessa J; Boeckle S; Beck H; Buckel T; Schlicht S; Ebeling M; Kiialainen A; Koulov A; Boll B; Weiser T; Singer T; Rolink AG; Iglesias A
    Pharm Res; 2015 Jul; 32(7):2344-59. PubMed ID: 25630815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of Bioproducts: Cellular Models to Evaluate the Impact of Therapeutic Antibody Aggregates.
    Nabhan M; Pallardy M; Turbica I
    Front Immunol; 2020; 11():725. PubMed ID: 32431697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a Heat Shock Protein Impurity on the Immunogenicity of Biotherapeutic Monoclonal Antibodies.
    Rane SS; Dearman RJ; Kimber I; Uddin S; Bishop S; Shah M; Podmore A; Pluen A; Derrick JP
    Pharm Res; 2019 Feb; 36(4):51. PubMed ID: 30771015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggregation of Recombinant Monoclonal Antibodies and Its Role in Potential Immunogenicity.
    Ignjatovic J; Svajger U; Ravnikar M; Molek P; Zadravec D; Paris A; Strukelj B
    Curr Pharm Biotechnol; 2018; 19(4):343-356. PubMed ID: 29874996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and consequences of recombinant protein isoforms: implications for biological potency.
    Federici MM; Venkat K; Bam N; Patel K; Dal Monte PR; Fernie B; Hensley P; Carr S; Baldoni J; Truneh A; Erickson J
    Dev Biol (Basel); 2003; 113():53-7; discussion 113-4. PubMed ID: 14620852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro.
    Rombach-Riegraf V; Karle AC; Wolf B; Sordé L; Koepke S; Gottlieb S; Krieg J; Djidja MC; Baban A; Spindeldreher S; Koulov AV; Kiessling A
    PLoS One; 2014; 9(1):e86322. PubMed ID: 24466023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Immunogenicity of Biologic Therapies.
    Garcês S; Demengeot J
    Curr Probl Dermatol; 2018; 53():37-48. PubMed ID: 29131036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
    Mikulskis A; Yeung D; Subramanyam M; Amaravadi L
    J Immunol Methods; 2011 Feb; 365(1-2):38-49. PubMed ID: 21130095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.
    Higaki JN; Chakrabartty A; Galant NJ; Hadley KC; Hammerson B; Nijjar T; Torres R; Tapia JR; Salmans J; Barbour R; Tam SJ; Flanagan K; Zago W; Kinney GG
    Amyloid; 2016 Jun; 23(2):86-97. PubMed ID: 26981744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of protein aggregates of a monoclonal antibody generated by forced shaking stress with siliconized and nonsiliconized syringes in BALB/c mice.
    Uchino T; Miyazaki Y; Yamazaki T; Kagawa Y
    J Pharm Pharmacol; 2017 Oct; 69(10):1341-1351. PubMed ID: 28639328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.
    Jawa V; Cousens LP; Awwad M; Wakshull E; Kropshofer H; De Groot AS
    Clin Immunol; 2013 Dec; 149(3):534-55. PubMed ID: 24263283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.